Literature DB >> 425997

Central retinal vein occlusion associated with hemodialysis.

C H Barton, N D Vaziri.   

Abstract

Central retinal vein occlusion (CRVO) occurred in 3 of 15 maintenance hemodialysis patients over a two-week period. There have been no previous reports of this ophthalmologic catastrophe observed in the dialysis setting. Lupus nephritis, Henoch-Schönlein purpura and nephrosclerosis constituted the patients' major underlying diseases. Moderate hypertension was also present. Impaired vision of the left eye noted 24 to 36 hours following dialysis was the presenting symptom in all cases. Findings included decreased visual acuity, retinal vein engorgement, hemorrhage, and disc edema. All three patients subsequently lost the vision in their left eye (two received anticoagulation therapy). With the exception of hypertension, there were no known underlying predisposing conditions present. Although we are unable to offer a definite explanation for these unusual cases of CRVO, we feel a hypercoagulable state may have been responsible. Because our three cases occurred during a two-week period, some transient unidentified procoagulant factor associated with hemodialysis could have been present.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 425997     DOI: 10.1097/00000441-197901000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Henoch-Schonlein purpura with bilateral central retinal artery occlusion.

Authors:  T-T Wu; S-J Sheu; L-C Chou; T-T Wu; S-J Sheu; S-J Sheu
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

2.  Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences?

Authors:  Anis Larakeb; Sandrine Leroy; Véronique Frémeaux-Bacchi; Marta Montchilova; Béatrice Pelosse; Olivier Dunand; Georges Deschênes; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2007-07-10       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.